StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Reiterates Buy Rating on Abbvie (ABBV) Despite Humira Erosion, With Focus on Skyrizi/Rinvoq
July 29, 2022 3:31 PM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $160.00 price target on Abbvie (NYSE: ABBV) following results, which ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View